Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Medical Officer | January 23, 2019 | January 25, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date January 23, 2019 · Filed January 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.93 · Expires 2029-01-23 | Direct | 60,000 |
Reported balance
After 2019-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-23 · Grant · Acquired 60,000 · Balance 60,000 F1: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2019 Filed Jan 25, 2019 22:08 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0000899243-19-001960 · doc4.xml · derivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,370 | $32.24 | $44,174.42 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 4 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,092 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 31,426 | $31.41 | $987,147.23 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 3 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,462 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $31.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 6,154 | $30.21 | $185,900.03 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 2 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,888 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,200 | $29.94 | $35,923.68 |
DisclosureSEC source: 0000899243-18-030087 · doc4.xml · nonDerivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,042 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $29.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 11:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 100 | $34.90 | $3,490.00 |
DisclosureSEC source: 0000899243-18-029425 · doc4.xml · nonDerivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,242 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 01:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,061 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004339 · doc4.xml · derivative · entry 1 Quiroz Jorge Armando · CIK 0001727401 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,061 Underlying: Common Stock · 47,061 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.